LexDanaLexDanabeta
Inventor

Andrew Karl DILGER

Inventor
US

Overview

3→
Patents
2024–2025
Patent span
Human necessities
Primary field (CPC A)

Patents· 3 as inventor

Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.

A61Kprimary
A61KPreparations for medical, dental or toiletry purposes30%
A61PSpecific therapeutic activity of chemical compounds or medicinal preparations30%
C07DHeterocyclic compounds20%
C07KPeptides10%
G01NInvestigating or analysing materials by determining their chemical or physical properties10%
PatentTitleYear
12,209,086FGFR3 inhibitor compounds202512,065,505Antibodies and antigen binding peptides for factor XIa inhibitors and uses thereof202411,878,976FGFR3 inhibitor compounds2024

Career & activity timeline

Assembled from patent assignee/location history and declaration credentials.

2024–2025Patents assigned to LILLY CO ELI (2)· patent assignee history
2024Patents assigned to BRISTOL MYERS SQUIBB CO (1)· patent assignee history
2024Patents assigned to JANSSEN PHARMACEUTICALS INC (1)· patent assignee history
2024–2025Based in US· patent location history

Inventor activity

Assignee and location history derived from the patent record.

Assignees
AssigneePatentsSpan
LILLY CO ELI22024–2025
BRISTOL MYERS SQUIBB CO12024
JANSSEN PHARMACEUTICALS INC12024
Locations
LocationPatentsSpan
US32024–2025